Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Sotorasib is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Peritoneal Cancer.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab ...

A protein kinase inhibitor is a type of enzyme inhibitor that can block the action of protein kinases. Protein kinase inhibitors can be subdivided according to the amino acid on a protein that they ...

Amgen Limited has received approval for tarlatamab (Imdyllytra) from the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adult patients with small cell lung ...

CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T ...

Japan’s pet cancer therapeutics sector surges forward, propelled by evolving diagnostic tools, innovative drug breakthroughs, ...

He, H.J., Cen, X.H., Liang, Y.J., Zhong, J.M., Deng, J.H. and Jiang, Y.J. (2025) Progress in the Regulation of Lipid Metabolism by the Orphan Nuclear Receptor Nur77. Journal of Biosciences and ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...